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X-linked Chronic Granulomatous Disease (X-CGD) is a rare, devastating primary 
immunodeficiency disorder (PID), characterised by defective host defence against certain 
bacteria and fungi.1 It is caused by mutations in the CYBB gene, encoding the gp91phox 
subunit of NADPH oxidase, an enzyme complex responsible for pathogen clearance in 
professional phagocytic cells. As for many monogenic disorders of the immune system, X-
CGD is amenable to gene therapy through gene addition. More recently, scientists have also 
started to explore nuclease-mediated targeted gene insertion as a strategy to restore 
gp91phox expression in reprogrammed stem cells (iPSCs) 2-4 and Haematopoietic Stem and 
Progenitor cells (HSPC) 5 from CGD patients. In this current paper, Sweeny et al. [ref 6], 
show that nuclease-mediated insertion of a CYBB minigene into exon 2, but surprisingly not 
exon 1, can restore gp91phox protein expression in iPSCs -derived granulocytes from X-CGD 
patients (Figure 1). This study highlights the importance of intronic elements for the 
expression of the CYBB gene by the endogenous regulatory elements and cautions those 
developing strategies for genetic correction by targeted insertion of minigenes. 
HSPC gene therapy by the use of viral vectors, has proven to be an effective 
therapeutic option for a series of PIDs. However, previous clinical trials for CGD, based on 
the use of gamma retroviral vectors, have in general failed to demonstrate significant long 
term engraftment of gene corrected cells in the absence of mutagenic proliferation of 
myeloid precursors.7 The recent introduction of lentiviral vectors with myeloid regulatory 
elements may not only improve safety by obviating enhancer-mediated mutagenesis in 
HSPCs, but may also enhance gene expression towards more physiological levels. Clinical 
trials in US and Europe are currently underway.  Alternatively, transposon-mediated 
integration of a BAC vector carrying the whole genomic region of the CYBB gene has been 
shown to rescue the CGD phenotype in granulocytes derived from iPSCs.8 However, clinical 
application of BAC trans-genesis for the gene therapy of CGD or other disorders is 
challenging because of the size of payload required to deliver the necessary regulatory 
elements as well as the coding sequence.  
DNA editing techniques have opened up new exciting avenues for gene therapy of 
genetic disorders. 9 Scientists can now use target directed nucleases to create a double 
strand break anywhere in the genome, and insert a new DNA sequence into the break by 
Homology Directed Repair (HDR).  This approach has been used, for example, to insert 
minigenes and, among those, the CYBB minigene into the AAVS1 locus, a putative genomic 
safe harbour, also resistant to silencing. 2, 3, 5 Although in principle safe, this strategy is still 
not perfect, for there is only a partial rescue of NAPDH-oxidase function in fully 
differentiated neutrophils .  Alternatively, to capture the advantages of natural gene 
regulatory mechanisms, scientists can use engineered nucleases to insert a functional 
minigene near the transcription start site of the disease-causing gene, also taking advantage 
of the increased cutting efficiency of the nuclease in this part of the gene structure.10 The 
assumption here is that it will enable physiological expression of the protein of interest 
since transcription is driven by the gene’s own regulatory sequences. Another even more 
precise approach would be to repair the pathogenic mutations in situ. For example, efficient 
targeted repair of the beta globin gene has been achieved in HSPCs by combining the use 
CRISPR/Cas9 system with AAV6-mediated delivery of a homologous donor template.11 
However, for the majority of genetic disorders where mutations can be spread across the 
whole gene, the wider application of this approach seems at present unlikely particularly for 
future commercial development.   
 The optimization of protocols to differentiate iPSCs into neutrophils 3 has given 
impetus to study new gene therapy approaches for CGD as well as to find ways to use those 
cells as potential source for therapeutic granulocyte infusion. In this paper, Sweeny et al., 
have compared different gene editing strategies for the correction of the X-CGD phenotype 
using iPSCs-derived granulocytes from CGD patients. Firstly, they accurately corrected the 
CYBB gene in iPSCs cells from patients bearing a 458T>G mutation or a 461(A) deletion in 
the exon 5. For this purpose they nucleofected TALEN or CRISPR/Cas9 expression plasmids 
targeting exon 5 together with a donor plasmid bearing the correct homologous sequence, 
and excisable selection markers. Clones that had undergone granulocytic differentiation 
exhibited almost normal levels of gp91phox expression and NADPH oxidase function. 
Remarkably, the team also detected normal expression levels of the CD13 marker 
suggesting that gene repair had unexpectedly contributed to normal granulocytic 
differentiation in CGD cells.  
They next devised a universal strategy to complement almost all gene mutations. For 
this purpose, they nucleofected TALENs or CRISPR/Cas9 plasmids targeting exon 1 or exon 2 
of the CYBB locus together with a plasmid containing two versions of the CYBB mini gene 
(exon 1-13 or exon 2 -13). They showed that TALEN -mediated insertion of a complete CYBB 
minigene exon 1-13 at the transcription start site of the gene (Figure 1a), did not lead to 
gp91phox expression or NADPH oxidase activity. In contrast,  CRISPR/Cas9 -mediated 
insertion of the CYBB exon 2-13 mini gene at the exon 2 site (Figure 1b) restored levels of 
gp91phox and of NADPH oxidase activity that were 64-100% and 68-100% of those obtained 
in control blood, respectively. Notably, expression of gp91phox was strictly myeloid-specific 
as the protein was only found in the CD13 positive population. The different outcomes of 
the two strategies suggest that an intact exon/intron 1 is key for normal endogenous 
expression of gp91phox. This should not come as too much of a surprise as it is widely 
recognised that intronic sequences can play a crucial role in normal gene expression. 
Intronic regions have also been used to boost gene expression or guide transcription in a 
tissue/stage specific manner. 12  
Although the authors did not investigate the mechanisms by which intron 1 controls 
expression of the CYBB gene, it is possible that the faulty correction arises from a lack of 
exon/intron splicing, the absence of an Exon/Junction complex signature, or the loss of 
enhancer elements that impairs expression of the CYBB minigene exon 1-13 from its own 
promoter.  Promoter-proximal introns often contain recruitment sites for enhancers or 
silencers. Maintaining early introns, as recently done for targeted editing of the Wiskott 
Aldrich Syndrome gene13, may therefore be a valid strategy for gene correction. As the 
authors rightly point out in the discussion, putative NF-kB binding sites are present in the 
first two introns of CYBB, suggesting that these could behave as enhancers. This is in line 
with the observation made by others that a minimal CYBB gene promoter is not sufficient to 
drive normal levels of expression of the protein in the context of lentiviral vectors. 14 
The use of selectable markers in the targeting constructs precludes evaluation of the 
efficiency of repair.  Nevertheless, the message of this study remains strong and clear. A 
careful analysis of the different elements required for physiological levels of gene 
expression is an essential step for emerging gene editing technologies as it will ultimately 
dictate the optimal strategy to achieve therapeutic levels of correction.  
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Figure Legend 
Figure 1. Overview of the gene targeting strategies devised by Sweeny et al. 
6
 
 
to comple-
ment  CYBB  gene mutations in induced pluripotent stem cells (iPSCs)  from patients with 
X-linked chronic granulomatous disease (X-CGD). Rescue of the Gp91phox protein expres-
sion in X-CGD iPSC-derived granulocytes by CRISPR/Cas9 -mediated insertion of the CYBB 
exon 2-13 mini gene at the exon 2 site A) but not by TALEN -mediated insertion of a com-
plete CYBB minigene exon 1-13 at the exon 1 site B). 
 
 
 
 
 
 
 
 
